Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels

This study was an observational study, and about 40 patients with intermediate and high risk myelofibrosis who had participated in any previous clinical study of Gecacitinib hydrochloride and were still receiving Gecacitinib treatment in our center were expected to be enrolled. There was no additional drug intervention, only the myelofibrosis grade and gene mutation level of the patients were collected. Subjects who met all inclusion criteria and none of the exclusion criteria were eligible for inclusion in this study. After informed consent was obtained and screening was successful, bone marrow aspiration, bone marrow biopsy, and gene mutation testing were performed once. If bone marrow was extracted, peripheral blood could be used for gene mutation testing, and then annually until the permanent discontinuation of Gecacitinib.

NCT Number	NCT07342712
Lead Sponsor	First Affiliated Hospital of Zhejiang University
Conditions	Myelofibrosis
Enrollment	40 participants
Start Date	2025-08-01
Primary Completion	2026-04-01 (estimated)
Study Completion	2027-12-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-15